Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Tria
Digital
- Autores:
-
Bosch, Jackie
Lonn, Eva
Dagenais, Gilles
Gao, Peggy
Lopez-Jaramillo, Patricio
Zhu, Jun
Pais, Prem
Avezum, Alvaro
Sliwa, Karen
Chazova, Irina E.
Peters, Ron
Held, Claes
Yusoff, Khalid
Lewis, Basil S.
Toff, William D.
Khunti, Kamlesh
Reid, Christopher M.
Leiter, Lawrence A.
Yusuf, Salim
Hart, Robert G.
The HOPE-3 Investigators
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2021
- Institución:
- Universidad de Santander
- Repositorio:
- Repositorio Universidad de Santander
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.udes.edu.co:001/6131
- Acceso en línea:
- https://doi.org/10.1161/STROKEAHA.120.030790
https://repositorio.udes.edu.co/handle/001/6131
- Palabra clave:
- Blood pressure
Candesartan
Cardiovascular disease
Primary prevention
Statin
Lipoprotein
- Rights
- openAccess
- License
- © 2021 The Authors, American Heart Association, Inc.
| id |
RUDES2_8fa75ed080557d830bfabc6a7cc436a0 |
|---|---|
| oai_identifier_str |
oai:repositorio.udes.edu.co:001/6131 |
| network_acronym_str |
RUDES2 |
| network_name_str |
Repositorio Universidad de Santander |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Tria |
| title |
Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Tria |
| spellingShingle |
Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Tria Blood pressure Candesartan Cardiovascular disease Primary prevention Statin Lipoprotein |
| title_short |
Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Tria |
| title_full |
Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Tria |
| title_fullStr |
Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Tria |
| title_full_unstemmed |
Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Tria |
| title_sort |
Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Tria |
| dc.creator.fl_str_mv |
Bosch, Jackie Lonn, Eva Dagenais, Gilles Gao, Peggy Lopez-Jaramillo, Patricio Zhu, Jun Pais, Prem Avezum, Alvaro Sliwa, Karen Chazova, Irina E. Peters, Ron Held, Claes Yusoff, Khalid Lewis, Basil S. Toff, William D. Khunti, Kamlesh Reid, Christopher M. Leiter, Lawrence A. Yusuf, Salim Hart, Robert G. The HOPE-3 Investigators |
| dc.contributor.author.none.fl_str_mv |
Bosch, Jackie Lonn, Eva Dagenais, Gilles Gao, Peggy Lopez-Jaramillo, Patricio Zhu, Jun Pais, Prem Avezum, Alvaro Sliwa, Karen Chazova, Irina E. Peters, Ron Held, Claes Yusoff, Khalid Lewis, Basil S. Toff, William D. Khunti, Kamlesh Reid, Christopher M. Leiter, Lawrence A. Yusuf, Salim Hart, Robert G. The HOPE-3 Investigators |
| dc.contributor.researchgroup.spa.fl_str_mv |
Masira |
| dc.subject.proposal.eng.fl_str_mv |
Blood pressure Candesartan Cardiovascular disease Primary prevention Statin |
| topic |
Blood pressure Candesartan Cardiovascular disease Primary prevention Statin Lipoprotein |
| dc.subject.proposal.spa.fl_str_mv |
Lipoprotein |
| description |
Digital |
| publishDate |
2021 |
| dc.date.issued.none.fl_str_mv |
2021-05-14 |
| dc.date.accessioned.none.fl_str_mv |
2022-02-23T16:45:47Z |
| dc.date.available.none.fl_str_mv |
2022-02-23T16:45:47Z |
| dc.type.spa.fl_str_mv |
Artículo de revista |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
| dc.type.content.spa.fl_str_mv |
Text |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/ART |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_6501 |
| status_str |
publishedVersion |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1161/STROKEAHA.120.030790 |
| dc.identifier.uri.none.fl_str_mv |
https://repositorio.udes.edu.co/handle/001/6131 |
| url |
https://doi.org/10.1161/STROKEAHA.120.030790 https://repositorio.udes.edu.co/handle/001/6131 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.citationendpage.spa.fl_str_mv |
2501 |
| dc.relation.citationissue.spa.fl_str_mv |
8 |
| dc.relation.citationstartpage.spa.fl_str_mv |
2494 |
| dc.relation.citationvolume.spa.fl_str_mv |
52 |
| dc.relation.indexed.spa.fl_str_mv |
Scopus |
| dc.relation.ispartofjournal.spa.fl_str_mv |
Stroke |
| dc.rights.spa.fl_str_mv |
© 2021 The Authors, American Heart Association, Inc. |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.creativecommons.spa.fl_str_mv |
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc/4.0/ |
| rights_invalid_str_mv |
© 2021 The Authors, American Heart Association, Inc. Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.extent.spa.fl_str_mv |
8 p |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
Stroke |
| dc.publisher.place.spa.fl_str_mv |
USA |
| dc.source.spa.fl_str_mv |
https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.120.030790 |
| institution |
Universidad de Santander |
| bitstream.url.fl_str_mv |
https://repositorio.udes.edu.co/bitstreams/3181af2a-9e8b-4331-8eb4-a57700bd826b/download https://repositorio.udes.edu.co/bitstreams/11bc8343-29de-4582-b8ba-1d68d55a0c3c/download https://repositorio.udes.edu.co/bitstreams/d0f3e640-f367-4b6d-b249-33019d52ca50/download https://repositorio.udes.edu.co/bitstreams/abbadc7d-deb9-4a9f-ae27-93fbf83ca60a/download |
| bitstream.checksum.fl_str_mv |
38d94cf55aa1bf2dac1a736ac45c881c 64ff3211fd02a4597db10bd3cbf45b20 5dbe86c1111d64f45ba435df98fdc825 8e66cecdf7643ec6b6827669312a541f |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Universidad de Santander |
| repository.mail.fl_str_mv |
soporte@metabiblioteca.com |
| _version_ |
1814158645999435776 |
| spelling |
Bosch, Jackie503f2202-0dda-463c-acc9-f5888e895278-1Lonn, Eva7a977a4b-14e3-44cc-8057-933d424aaa9b-1Dagenais, Gillesc865f015-4dc7-483d-9dae-132288d901f8-1Gao, Peggy46954da1-6290-4040-9c8c-33dcfaf225dd-1Lopez-Jaramillo, Patricio9a71267b-dcb0-4d31-b37d-2d30be58d4d2-1Zhu, Jund97cdbd2-6a82-430c-abfe-c978f085997e-1Pais, Prem5abdbf77-3c3f-4396-8634-83723aa215b9-1Avezum, Alvaro8b920360-abb2-4ec8-b5ee-4e3f4e0b11eb-1Sliwa, Karen7ff2b80f-9412-4d65-99cd-7d01d5578687-1Chazova, Irina E.367fe97b-a5c9-4bf0-8cd2-5a526deafa35-1Peters, Ronfb29ef3f-47e7-4ed4-8b39-18672ff00fd8-1Held, Claes76b69ce8-c468-49c5-8d48-95a823d8b565-1Yusoff, Khalid933db13d-f5bb-4ea6-91a5-68eea1ca9ffc-1Lewis, Basil S.a8106b8e-2b4b-412e-90c7-4012b1272405-1Toff, William D.97acb6df-c33b-45ad-b772-c52ac4aa7281-1Khunti, Kamleshe9aff03a-6f97-433d-a56e-8d7f703caa03-1Reid, Christopher M.7d8a8211-12ad-464c-948d-16952b66144d-1Leiter, Lawrence A.bcdd3211-40b7-474d-9f6c-8a1051ceb9bf-1Yusuf, Salim06a836b5-f5e3-41d9-a516-9cc46e5d7948-1Hart, Robert G.c9285249-036e-4d00-9881-f77d5290af09-1The HOPE-3 Investigatorsad5cd98d-86e0-4739-a226-91ef50ed152c-1Masira2022-02-23T16:45:47Z2022-02-23T16:45:47Z2021-05-14DigitalBackground and Purpose: The HOPE-3 trial (Heart Outcomes Prevention Evaluation–3) found that antihypertensive therapy combined with a statin reduced first stroke among people at intermediate cardiovascular risk. We report secondary analyses of stroke outcomes by stroke subtype, predictors, treatment effects in key subgroups. Methods: Using a 2-by-2 factorial design, 12 705 participants from 21 countries with vascular risk factors but without overt cardiovascular disease were randomized to candesartan 16 mg plus hydrochlorothiazide 12.5 mg daily or placebo and to rosuvastatin 10 mg daily or placebo. The effect of the interventions on stroke subtypes was assessed. Results: Participants were 66 years old and 46% were women. Baseline blood pressure (138/82 mm Hg) was reduced by 6.0/3.0 mm Hg and LDL-C (low-density lipoprotein cholesterol; 3.3 mmol/L) was reduced by 0.90 mmol/L on active treatment. During 5.6 years of follow-up, 169 strokes occurred (117 ischemic, 29 hemorrhagic, 23 undetermined). Blood pressure lowering did not significantly reduce stroke (hazard ratio [HR], 0.80 [95% CI, 0.59–1.08]), ischemic stroke (HR, 0.80 [95% CI, 0.55–1.15]), hemorrhagic stroke (HR, 0.71 [95% CI, 0.34–1.48]), or strokes of undetermined origin (HR, 0.92 [95% CI, 0.41–2.08]). Rosuvastatin significantly reduced strokes (HR, 0.70 [95% CI, 0.52–0.95]), with reductions mainly in ischemic stroke (HR, 0.53 [95% CI, 0.37–0.78]) but did not significantly affect hemorrhagic (HR, 1.22 [95% CI, 0.59–2.54]) or strokes of undetermined origin (HR, 1.29 [95% CI, 0.57–2.95]). The combination of both interventions compared with double placebo substantially and significantly reduced strokes (HR, 0.56 [95% CI, 0.36–0.87]) and ischemic strokes (HR, 0.41 [95% CI, 0.23–0.72]). Conclusions: Among people at intermediate cardiovascular risk but without overt cardiovascular disease, rosuvastatin 10 mg daily significantly reduced first stroke. Blood pressure lowering combined with rosuvastatin reduced ischemic stroke by 59%. Both therapies are safe and generally well tolerated.Correction to: Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 TrialCiencias Médicas y de la Salud8 papplication/pdfhttps://doi.org/10.1161/STROKEAHA.120.030790https://repositorio.udes.edu.co/handle/001/6131engStrokeUSA25018249452ScopusStroke© 2021 The Authors, American Heart Association, Inc.info:eu-repo/semantics/openAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_abf2https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.120.030790Blood pressureCandesartanCardiovascular diseasePrimary preventionStatinLipoproteinAntihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 TriaArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85Todas las AudienciasPublicationLICENSElicense.txtlicense.txttext/plain; charset=utf-859https://repositorio.udes.edu.co/bitstreams/3181af2a-9e8b-4331-8eb4-a57700bd826b/download38d94cf55aa1bf2dac1a736ac45c881cMD52ORIGINALAntihypertensives and Statin Therapy for Primary Stroke Prevention. A Secondary Analysis of the HOPE-3 Tria.pdfAntihypertensives and Statin Therapy for Primary Stroke Prevention. A Secondary Analysis of the HOPE-3 Tria.pdfapplication/pdf227615https://repositorio.udes.edu.co/bitstreams/11bc8343-29de-4582-b8ba-1d68d55a0c3c/download64ff3211fd02a4597db10bd3cbf45b20MD51TEXTAntihypertensives and Statin Therapy for Primary Stroke Prevention. A Secondary Analysis of the HOPE-3 Tria.pdf.txtAntihypertensives and Statin Therapy for Primary Stroke Prevention. A Secondary Analysis of the HOPE-3 Tria.pdf.txtExtracted texttext/plain5https://repositorio.udes.edu.co/bitstreams/d0f3e640-f367-4b6d-b249-33019d52ca50/download5dbe86c1111d64f45ba435df98fdc825MD53THUMBNAILAntihypertensives and Statin Therapy for Primary Stroke Prevention. A Secondary Analysis of the HOPE-3 Tria.pdf.jpgAntihypertensives and Statin Therapy for Primary Stroke Prevention. A Secondary Analysis of the HOPE-3 Tria.pdf.jpgGenerated Thumbnailimage/jpeg10645https://repositorio.udes.edu.co/bitstreams/abbadc7d-deb9-4a9f-ae27-93fbf83ca60a/download8e66cecdf7643ec6b6827669312a541fMD54001/6131oai:repositorio.udes.edu.co:001/61312023-10-09 18:05:39.909https://creativecommons.org/licenses/by-nc/4.0/© 2021 The Authors, American Heart Association, Inc.https://repositorio.udes.edu.coRepositorio Universidad de Santandersoporte@metabiblioteca.comTGljZW5jaWEgZGUgUHVibGljYWNpw7NuIFVERVMKRGlyZWN0cmljZXMgZGUgVVNPIHkgQUNDRVNPCgo= |